Succimer

Summary

Succimer (CHEMBL1201073) is an approved small-molecule chelator; indicated across 6 conditions including autism and myelodysplastic syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 8
• Chemistry: 182.2 Da · C4H6O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201073
Name	Succimer
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2724354
ChEBI	CHEBI:63623
Molecular formula	C4H6O4S2
Molecular weight	182.2
InChIKey	ACTRVOBWPAIOHC-XIXRPRMCSA-N

SMILES: [C@@H]([C@@H](C(=O)O)S)(C(=O)O)S

IUPAC name: (2S,3R)-2,3-bis(sulfanyl)butanedioic acid

ChEBI definition: A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.

Pharmacological roles (ChEBI): chelator.

Also known as: Chemet, DIM-SA, DMS-A, DMSA, Succimer, Succimero, SUCCIMER, DIMERCAPTOSUCCINIC-ACID, Dimercaptosuccinic_acid, dimercaptosuccinic-acid, succimer

Patent coverage: 3,826 distinct patent families (10,987 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Prothrombin, Replicase polyprotein 1ab, Bile salt export pump.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0DTD1	5.76	IC50	1720	nM	CHEMBL_ACT_19964309
F2	5.58	AC50	2640	nM	CHEMBL_ACT_25196509

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
autism	2	MONDO:0005260	EFO:0003758
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
chronic myeloid leukemia	1	MONDO:0011996	EFO:0000339
Wilson disease	0	MONDO:0010200	MONDO:0010200

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	2
Not specified	2
PHASE4	1
PHASE3	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03123237	PHASE4	UNKNOWN	Quantitative Renal Uptake Using TC99m DMSA in Hypertensive &/or Diabetic Patients.
NCT00342849	PHASE3	COMPLETED	Treatment of Lead-Exposed Children Trial
NCT06811233	PHASE2	RECRUITING	Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
NCT00376194	PHASE2	WITHDRAWN	Mercury Chelation to Treat Autism
NCT03630991	PHASE1	RECRUITING	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
NCT03957720	EARLY_PHASE1	UNKNOWN	The Individual Therapy for Patients With Wilson’s Disease
NCT00004838	Not specified	COMPLETED	Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children
NCT00374894	Not specified	COMPLETED	The Combined Effect of 2,3-Dimercaptosuccinic Acid and Multi-Nutrients on Children in Lead Poisoning

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).